Clinical trial · Interventional
Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. It is not yet known if the addition of photodynamic therapy to combined therapy with surgery, radiation therapy, and chemotherapy is more effective than combined therapy alone for supratentorial gliomas. PURPOSE: Randomized phase III trial to study the effectiveness of surgery, radiation therapy, and chemotherapy with or without photodynamic therapy in treating patients who have newly diagnosed or recurrent malignant supratentorial gliomas.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carmustine | Drug | Carmustine | ALIAS |
| lomustine | Drug | Lomustine | ALIAS |
| neoadjuvant therapy | Procedure | — | UNRESOLVED |
| porfimer sodium | Drug | Porfimer | ALIAS |
| procarbazine hydrochloride | Drug | Procarbazine | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| surgical procedure | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed newly diagnosed or recurrent supratentorial glioblastoma or malignant astrocytoma * Grade 3 or 4 astrocytoma as defined by the Daumas-Duport classification * Suitable for radical resection on the basis of imaging studies * Patients with recurrent disease must have failed surgery and radiotherapy PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * Karnofsky 60-100% for newly diagnosed tumor * Karnofsky 70-100% for recurrent tumor Life expectancy: * At least 3 months Hematopoietic: * Recurrent tumor: * WBC at least 2,000/mm\^3 * Platelet count at least 80,000/mm\^3 Hepatic: * Recurrent tumor: * PT/PTT no greater than 1.5 times upper limit of normal (ULN) * Bilirubin and LFTs less than 2 times ULN * Alkaline phosphatase no greater than 3 times ULN * GGT no greater than 3 times ULN Renal: * Creatinine no greater than 2 mg/dL Other: * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * See Disease Characteristics * No prior cranial radiotherapy for newly diagnosed tumor Surgery: * See Disease Characteristics
References
Publications (0)
Data not yet available